RT Journal Article
SR Electronic
T1 HealthCall: Smartphone Enhancement of Brief Interventions to Improve Medication Adherence Among Patients in HIV care
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.25.20235788
DO 10.1101/2020.11.25.20235788
A1 Hasin, Deborah
A1 Aharonovich, Efrat
A1 Zingman, Barry
A1 Stohl, Malka
A1 Walsh, Claire
A1 Elliott, Jennifer C.
A1 Fink, David
A1 Knox, Justin
A1 Durant, Sean
A1 Menchaca, Raquel
A1 Sharma, Anjali
YR 2020
UL http://medrxiv.org/content/early/2020/11/26/2020.11.25.20235788.abstract
AB Background Heavy drinking among People Living With HIV (PLWH) reduces antiretroviral adherence and worsens health outcomes. Lengthy interventions to reduce drinking and improve adherence are not feasible in most HIV primary care settings, and patients seldom follow referrals to outside treatment. Utilizing visual and video features of smartphone technology, we developed and tested HealthCall as an electronic (smartphone) means of increasing patient involvement in brief intervention to reduce drinking and improve medication adherence without making unfeasible demands on providers.Methods Alcohol-dependent patients at a large urban HIV clinic were randomized to one of three groups: (1) Motivational Interviewing (MI) plus HealthCall (n=39), (2) NIAAA Clinician’s Guide (CG) plus HealthCall (n=38), or (3) CG-only (n=37). Baseline interventions targeting drinking reduction and medication adherence were ∼25 minutes, with brief (10-15 min) booster sessions at 30 and 60 days. HealthCall involved daily use of the smartphone for 3-5 min/day, covering drinking, medication adherence, and other aspects of the prior 24 hours. Our outcome, assessed at 30 and 60 days, and 3, 6 and 12 months, was ART adherence (using unannounced phone pill-count method; possible adherence scores: 0%-100%). Analysis: generalized linear mixed models with pre-planned contrasts.Results Study retention was excellent (85%-94% across timepoints) and unrelated to treatment arm or patient characteristics. ART adherence was generally high throughout follow-up, with some decline by 12 months. Although both CG+HealthCall and MI+HealthCall evidenced benefits early in follow-up, by 6 months, ART adherence was 11% better among patients in CG+HealthCall than in CG-only (p=0.03) and 9% better than among patients in MI+HealthCall (p=0.07). Efficacy differed slightly by gender (p=.09).Conclusion HealthCall paired with CG resulted in better ART adherence than CG alone. MI+HealthCall’s early benefits diminished over time. Given the importance of ART adherence and drinking reduction among PLWH, and the low costs and time required for HealthCall, pairing HealthCall with brief interventions within HIV clinics merits widespread consideration.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial02501057Funding StatementR01 AA023163Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review boards at the New York State Psychiatric Institute (Research Foundation for Mental Hygiene) and Montefiore Hospital, Bronx, New York approved all procedures under grant number R01AA023163.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPatient data is confidential and protected. Please contact dsh2@cumc.columbia.edu with questions.